Website: abzymetx.com | LinkedIn: linkedin.com/company/abzymetherapeutics
Small Domains. Big Impact.
How Dr. Hiep Tran and Abzyme Therapeutics are engineering antibodies that switch on where they are needed
At a glance
- Company: Abzyme Therapeutics (abzymetx.com)
- Founded: 2010, Greater Philadelphia
- Focus: Antibody discovery, directed evolution, and conditionally active antibody engineering
- Business model: Contract research, co-development, and licensing
- Working with PSG on: Business development for CRO services and antibody licensing
A scientist who builds platforms, not just molecules
Most biotechs are built around one molecule. Abzyme is built around a scientist who keeps finding better ways to make them.
Dr. Hiep Tran, co-founder and Chief Scientific Officer, has been solving hard biology problems for more than three decades. He won a silver medal for Vietnam at the 1983 International Mathematical Olympiad, earned his PhD in Molecular Genetics with highest honors from Leningrad State University, and trained at the NIH’s National Institute of Environmental Health Sciences, where he studied DNA recombination, repair, replication, and mutagenesis.
That early work in mutagenesis became the foundation for everything that followed. After leading R&D at LifeSensors and directing Molecular Biology Services at Rockland Immunochemicals, Hiep co-founded Abzyme in 2010 to put directed evolution to work on therapeutic antibodies.
His record speaks for itself: 26+ peer-reviewed publications, five issued U.S. patents with more pending, an invention featured in The Economist’s Technology Quarterly, and multiple NIH, USDA, and DoD SBIR awards as Principal Investigator.
The science: antibodies that read their environment
One of oncology’s hardest problems is on-target, off-tumor toxicity. The target shows up in healthy tissue too, so a potent antibody hits both.
Abzyme’s answer is to engineer antibodies that respond to where they are. Using its patented yeast-display directed evolution platform, the team has developed pH-dependent antibodies, including an anti-CD3 designed to bind preferentially in the acidic tumor microenvironment, for safer T-cell engagers in solid tumors.
The same engine powers a deep modular toolkit:
- Camelid VHH (nanobody) discovery from proprietary yeast-display libraries, screening up to 10 targets in parallel
- Affinity maturation and directed evolution of existing biologics for new specificity, affinity, or environment-dependent binding
- Bispecific and multispecific engineering across IgG-VHH, Fab, and VHH-VHH formats
- Engineered checkpoint receptors, including a PD-1 variant that blocks both PD-L1 and PD-L2, and an HVEM variant that blocks BTLA and CD160 while sparing LIGHT
- Abz880, a PD-L1/PD-L2 x VEGF triple blocker built for one of the most active areas in oncology dealmaking
Proven with pharma
Abzyme’s platform isn’t theoretical. The company has completed fee-for-service antibody engineering for a top-20 pharma company, and its issued pH-dependent anti-CD3 patent is licensed non-exclusively to multiple partners.